Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients [1]

Bone Marrow Transplantation

Volumn 36, Issue 2, 2005, Pages 177-

  Brown, J ^a   Freeman, B B ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAZOLE DERIVATIVE; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ASPERGILLOSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; HUMAN; KIDNEY FAILURE; LETTER; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RECIPIENT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 22744445226     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705012     Document Type: Letter

References (8)

1. Trifilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509-513.
2. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002; 35: 1273-1275.
3. Evans WE. General principles of applied pharmacokinetics. In: Evans WE, Schentag JJ, Jusko WJ (eds). Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Applied Therapeutics Inc.: Vancouver, WA, 1992, pp 1-2.
4. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
5. Radford SA, Johnson EM, Warnock DW. In vitro studies of activities of voriconazole (UK 109,396) a new triazole anti-fungal agent, against emerging and less common mold pathogens. Antimicrob Agent Chemother 1997; 41: 841-843.
6. Espinen-Ingroff A. In vitro activity of the new triazole voriconazole (UK 109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microb 1998; 36: 198-202.
7. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-3169.
8. Vfend Package Insert (2002).